Abstract 5437
Background
Apoptosis has a central role in the process of oral mucositis and can be sustained by proinflammatory cytokines. Some studies have demonstrated increased levels of tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β) and interleukin 6 (IL-6) in saliva after radiotherapy and chemotherapy, which has been associated to severe oral mucositis. However, little is known about the role of these cytokines in the pro and anti-apoptosis process of oral cells exposed to antineoplastic agents. The aim of this study was to verify whether there was an association of salivary cytokines with oral cells exhibiting apoptosis or anti-apoptotic Bcl-2 expression in patients who experienced oral mucositis during hematopoietic cell transplantation (HCT).
Methods
We collected saliva and oral mucosa cells from 77 HCT patients before the conditioning (T0), during the neutropenia period (T1), and after the marrow recovery (T2). We quantified the oral exfoliated cells exhibiting TUNEL positivity and immunocytochemical expression of Bcl-2. We also determined the salivary levels of TNF-α, IL-1β, and IL-6 in the three periods.
Results
The number of cells exhibiting positivity to TUNEL (p = 0.021) and Bcl-2 (p = 0.020) increased from T0 to T2. The levels of TNF-α increased significantly from T0 to T1 (p < 0.001). There were no significant alterations of IL-1β and IL-6 comparing the three periods. There was a significant positive correlation between TNF-α and TUNEL in T0 (rho=0.277, p = 0.033) and T1 (rho=0.451, p = 0.020). Bcl-2 expression in T1 (rho=--0.335, p = 0.048) was negatively correlated with time duration of oral mucositis.
Conclusions
Oral cells exhibited apoptosis even after the marrow recovery. Oral cells apoptosis was associated with salivary TNF-α during the neutropenia period. Oral cells also exhibited high expression of antiapoptotic protein Bcl-2, which was inversely proportional to the duration of oral mucositis, suggesting the activation of a surveillance mechanism in the oral cells. Alterations on salivary TNF-α during the HCT may have a putative role in the apoptosis presented in oral mucositis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Israelita Albert Einstein.
Funding
São Paulo Research Foundation (2016/03650-4) and AmigoOH - Brazil.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population
Presenter: Baohui Han
Session: Poster Display session 1
Resources:
Abstract
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract